Thiazosulfone (also known as Promizole) is a phenylsulfonylthiazole derivative patented by Parke, Davis & Co. as the anti-tuberculosis agent. In preclinical models, Thiazosulfone exerts a definitely favorable influence on the course of experimental tuberculosis previously established in the highly susceptible guinea pig. In clinical trials Thiazosulfone and Streptomycin combined therapy exerts favor influences on tuberculous meningitis. Thiazosulfone seems to have an inhibitory action on hematogenous tuberculosis. Its toxicity is very low and it can, therefore, be administered for a prolonged period.